Abstract
Higher transmissibility of SARS-CoV-2 in cold and dry weather conditions has been hypothesized since the onset of the COVID-19 pandemic but the level of epidemiological evidence remains low.
During the first wave of the pandemic for Spain, Italy, France, Portugal, Canada and USA presented an early spread, a heavy COVID-19 burden, and low initial public health response until lockdowns. We used regional death counts as a proxy for infections while diagnostic tests remained limited and calculated a basic reproduction number (R0) in 63 regions. After adjusting for population density, early spread of the epidemic, and aged population, temperature and humidity were negatively associated to SARS-CoV-2 transmissibility. A −1g/m3 lower mean absolute humidity was associated with a 0.15-unit higher R0. Below 10°C, a 1°C-higher temperature was associated with a 0.16-unit lower R0.
Our results confirm a strong dependency of SARS-CoV-2 transmissibility to weather conditions in the absence of control measures. The initiation of the second wave in north-west hemisphere countries was likely triggered by the transition from summer- to winter-like conditions. High levels of restrictions to social activities should be maintained until spring to avoid or limit a third wave.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
not applicable: research involving spatially- and temporally aggregated data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The analysis was performed using openly accessible data. The links are provided in the supplementary material.
